{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T07:09:28Z","timestamp":1778310568068,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Department of Biotechnology, Govt. of India","award":["BT\/PR56465\/BMS\/85\/1471\/2025."],"award-info":[{"award-number":["BT\/PR56465\/BMS\/85\/1471\/2025."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Model"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00894-026-06727-2","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T06:48:15Z","timestamp":1776926895000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A structure-based virtual screening approach to identify novel anaplastic lymphoma kinase inhibitors"],"prefix":"10.1007","volume":"32","author":[{"given":"Kajal","family":"Sandhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibasis","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2930-7658","authenticated-orcid":false,"given":"S.","family":"Chockalingam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"6727_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.21037\/tro.2020.04.01","volume":"4","author":"CY Lee","year":"2020","unstructured":"Lee CY, Hsu YL, Lee MY et al (2020) Clinical significance of recombinant RANBP2-ALK oncogene to radiotherapy in a case of locally advanced rectal epithelioid inflammatory myofibroblastic sarcoma: case report and review of literature. Ther Radiol Oncol 4:9. https:\/\/doi.org\/10.21037\/tro.2020.04.01","journal-title":"Ther Radiol Oncol"},{"key":"6727_CR2","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2022.13397","volume":"24","author":"Y Lei","year":"2022","unstructured":"Lei Y, Lei Y, Shi X, Wang J (2022) EML4-ALK fusion gene in non-small cell lung cancer (Review). Oncol Lett 24:277","journal-title":"Oncol Lett"},{"key":"6727_CR3","first-page":"2020","volume":"17","author":"Z Cao","year":"2019","unstructured":"Cao Z, Gao Q, Fu M et al (2019) Anaplastic lymphoma kinase fusions: Roles in cancer and therapeutic perspectives (review). Oncol Lett 17:2020\u20132030","journal-title":"Oncol Lett"},{"key":"6727_CR4","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1080\/15384047.2015.1095407","volume":"16","author":"Z Zhao","year":"2015","unstructured":"Zhao Z, Verma V, Zhang M (2015) Anaplastic lymphoma kinase: role in cancer and therapy perspective. Cancer Biol Ther 16:1691\u20131701. https:\/\/doi.org\/10.1080\/15384047.2015.1095407","journal-title":"Cancer Biol Ther"},{"key":"6727_CR5","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/j.jpedsurg.2020.10.033","volume":"56","author":"Y Chen","year":"2021","unstructured":"Chen Y, Tsai HW, Tsai YH, Tseng SH (2021) VS-5584, a PI3K\/mTOR dual inhibitor, exerts antitumor effects on neuroblastomas in vitro and in vivo. J Pediatr Surg 56:1441\u20131448. https:\/\/doi.org\/10.1016\/j.jpedsurg.2020.10.033","journal-title":"J Pediatr Surg"},{"issue":"18","key":"6727_CR6","doi-asserted-by":"publisher","first-page":"8737","DOI":"10.18632\/oncotarget.2372","volume":"5","author":"NF Moore","year":"2014","unstructured":"Moore NF, Azarova AM, Bhatnagar N et al (2014) Molecular rationale for the use of PI3K\/AKT\/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma. Oncotarget 5(18):8737\u201349","journal-title":"Oncotarget"},{"key":"6727_CR7","doi-asserted-by":"publisher","first-page":"eaam7550","DOI":"10.1126\/scisignal.aam7550","volume":"10","author":"G Umapathy","year":"2017","unstructured":"Umapathy G, Guan J, Gustafsson DE et al (2017) MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas. Sci Signal 10:eaam7550. https:\/\/doi.org\/10.1126\/scisignal.aam7550","journal-title":"Sci Signal"},{"key":"6727_CR8","doi-asserted-by":"publisher","first-page":"ra102","DOI":"10.1126\/scisignal.2005470","volume":"7","author":"G Umapathy","year":"2014","unstructured":"Umapathy G, A El Wakil, Witek B et al (2014) The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma. Sci Signal 7:ra102. https:\/\/doi.org\/10.1126\/scisignal.2005470","journal-title":"Sci Signal"},{"key":"6727_CR9","doi-asserted-by":"publisher","first-page":"5269","DOI":"10.1111\/febs.12453","volume":"280","author":"K Sattu","year":"2013","unstructured":"Sattu K, Hochgr\u00e4fe F, Wu J et al (2013) Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells. FEBS J 280:5269\u20135282","journal-title":"FEBS J"},{"key":"6727_CR10","doi-asserted-by":"publisher","first-page":"22231","DOI":"10.1074\/jbc.M111145200","volume":"277","author":"G Piccinini","year":"2002","unstructured":"Piccinini G, Bacchiocchi R, Serresi M et al (2002) A ligand-inducible epidermal growth factor receptor\/anaplastic lymphoma kinase chimera promotes mitogenesis and transforming properties in 3T3 cells. J Biol Chem 277:22231\u201322239. https:\/\/doi.org\/10.1074\/jbc.M111145200","journal-title":"J Biol Chem"},{"key":"6727_CR11","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1158\/0008-5472.CAN-20-3351","volume":"81","author":"K Unno","year":"2021","unstructured":"Unno K, Chalmers ZR, Pamarthy S et al (2021) Activated ALK cooperates with N-Myc via Wnt\/\u03b2-catenin signaling to induce neuroendocrine prostate cancer. Cancer Res 81:2157\u20132170. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-3351","journal-title":"Cancer Res"},{"key":"6727_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26433","author":"C Angela","year":"2022","unstructured":"Angela C, Loretta S, Amy S et al (2022) Up-regulation of ALK is associated with altered Wnt\/beta-catenin pathway in adult pancreatoblastoma. Pediatr Blood Cancer. https:\/\/doi.org\/10.1002\/pbc.26433","journal-title":"Pediatr Blood Cancer"},{"key":"6727_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.113927","author":"M Huang","year":"2024","unstructured":"Huang M, Fang W, Farrel A et al (2024) ALK upregulates POSTN and WNT signaling to drive neuroblastoma. Cell Rep. https:\/\/doi.org\/10.1016\/j.celrep.2024.113927","journal-title":"Cell Rep"},{"key":"6727_CR14","doi-asserted-by":"publisher","first-page":"142413","DOI":"10.1016\/j.ijbiomac.2025.142413","volume":"308","author":"K Sandhu","year":"2025","unstructured":"Sandhu K, Sahoo S, Arulandu A, Chockalingam S (2025) Anaplastic lymphoma kinase enhances Wnt signaling through R-spondin: a new dimension to ALK-mediated oncogenesis. Int J Biol Macromol 308:142413. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.142413","journal-title":"Int J Biol Macromol"},{"key":"6727_CR15","doi-asserted-by":"publisher","first-page":"10927","DOI":"10.1021\/acs.jmedchem.9b00446","volume":"62","author":"X Kong","year":"2019","unstructured":"Kong X, Pan P, Sun H et al (2019) Drug discovery targeting anaplastic lymphoma kinase (ALK). J Med Chem 62:10927\u201310954. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b00446","journal-title":"J Med Chem"},{"key":"6727_CR16","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1042\/BJ20100609","volume":"430","author":"CC Lee","year":"2010","unstructured":"Lee CC, Jia Y, Li N et al (2010) Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. Biochem J 430:425\u2013437. https:\/\/doi.org\/10.1042\/BJ20100609","journal-title":"Biochem J"},{"key":"6727_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.808864","author":"S Liang","year":"2021","unstructured":"Liang S, Wang Q, Qi X et al (2021) Deciphering the mechanism of gilteritinib overcoming lorlatinib resistance to the double mutant I1171N\/F1174I in anaplastic lymphoma kinase. Front Cell Dev Biol. https:\/\/doi.org\/10.3389\/fcell.2021.808864","journal-title":"Front Cell Dev Biol"},{"key":"6727_CR18","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.ccr.2011.04.004","volume":"19","author":"H Sakamoto","year":"2011","unstructured":"Sakamoto H, Tsukaguchi T, Hiroshima S et al (2011) CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 19:679\u2013690. https:\/\/doi.org\/10.1016\/j.ccr.2011.04.004","journal-title":"Cancer Cell"},{"key":"6727_CR19","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1074\/jbc.M706067200","volume":"283","author":"CJ Tartari","year":"2008","unstructured":"Tartari CJ, Gunby RH, Coluccia AML et al (2008) Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase. J Biol Chem 283:3743\u20133750. https:\/\/doi.org\/10.1074\/jbc.M706067200","journal-title":"J Biol Chem"},{"key":"6727_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23071610","author":"CH Jiang","year":"2018","unstructured":"Jiang CH, Huang CX, Chen YJ et al (2018) Molecular modeling for structural insights concerning the activation mechanisms of F1174L and R1275Q mutations on anaplastic lymphoma kinase. Molecules. https:\/\/doi.org\/10.3390\/molecules23071610","journal-title":"Molecules"},{"key":"6727_CR21","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/nejmoa1311107","volume":"370","author":"AT Shaw","year":"2014","unstructured":"Shaw AT, Kim D-W, Mehra R et al (2014) Ceritinib in ALK -rearranged non\u2013small-cell lung cancer. N Engl J Med 370:1189\u20131197. https:\/\/doi.org\/10.1056\/nejmoa1311107","journal-title":"N Engl J Med"},{"key":"6727_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0251-8","volume":"9","author":"J Wu","year":"2016","unstructured":"Wu J, Savooji J, Liu D (2016) Second- and third-generation ALK inhibitors for non-small cell lung cancer. J Hematol Oncol 9:19","journal-title":"J Hematol Oncol"},{"key":"6727_CR23","first-page":"379","volume":"3","author":"SI Rothschild","year":"2014","unstructured":"Rothschild SI (2014) Ceritinib-a second-generation ALK inhibitor overcoming resistance in ALK-rearranged non-small cell lung cancer. Transl Lung Cancer Res 3:379\u2013381","journal-title":"Transl Lung Cancer Res"},{"key":"6727_CR24","doi-asserted-by":"publisher","first-page":"4408","DOI":"10.1158\/0008-5472.CAN-06-4443","volume":"67","author":"HY Zou","year":"2007","unstructured":"Zou HY, Li Q, Lee JH et al (2007) An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 67:4408\u20134417. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-4443","journal-title":"Cancer Res"},{"key":"6727_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-37240-z","author":"N Javanmardi","year":"2019","unstructured":"Javanmardi N, Fransson S, Djos A et al (2019) Low frequency ALK hotspots mutations in neuroblastoma tumours detected by ultra-deep sequencing: implications for ALK inhibitor treatment. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-018-37240-z","journal-title":"Sci Rep"},{"key":"6727_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10040113","author":"RM Trigg","year":"2018","unstructured":"Trigg RM, Turner SD (2018) ALK in neuroblastoma: biological and therapeutic implications. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers10040113","journal-title":"Cancers (Basel)"},{"key":"6727_CR27","doi-asserted-by":"publisher","DOI":"10.1101\/mcs.a001115","volume":"3","author":"VR Holla","year":"2017","unstructured":"Holla VR, Elamin YY, Bailey AM et al (2017) ALK: a tyrosine kinase target for cancer therapy. Mol Case Stud 3:a001115. https:\/\/doi.org\/10.1101\/mcs.a001115","journal-title":"Mol Case Stud"},{"key":"6727_CR28","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.semcancer.2011.09.005","volume":"21","author":"AM Azarova","year":"2011","unstructured":"Azarova AM, Gautam G, George RE (2011) Emerging importance of ALK in neuroblastoma. Semin Cancer Biol 21:267\u2013275","journal-title":"Semin Cancer Biol"},{"key":"6727_CR29","doi-asserted-by":"publisher","first-page":"10038","DOI":"10.1158\/0008-5472.CAN-10-2956","volume":"70","author":"T Sasaki","year":"2010","unstructured":"Sasaki T, Okuda K, Zheng W et al (2010) The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res 70:10038\u201310043. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-2956","journal-title":"Cancer Res"},{"key":"6727_CR30","doi-asserted-by":"publisher","first-page":"108ra114","DOI":"10.1126\/scitranslmed.3002950","volume":"3","author":"SC Bresler","year":"2011","unstructured":"Bresler SC, Wood AC, Haglund EA et al (2011) Neuroblastoma: Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med 3:108ra114. https:\/\/doi.org\/10.1126\/scitranslmed.3002950","journal-title":"Sci Transl Med"},{"key":"6727_CR31","doi-asserted-by":"publisher","first-page":"30239","DOI":"10.1039\/c7cp05418a","volume":"19","author":"J Chen","year":"2017","unstructured":"Chen J, Wang J, Zhu W (2017) Mutation L1196M-induced conformational changes and the drug resistant mechanism of anaplastic lymphoma kinase studied by free energy perturbation and umbrella sampling. Phys Chem Chem Phys 19:30239\u201330248. https:\/\/doi.org\/10.1039\/c7cp05418a","journal-title":"Phys Chem Chem Phys"},{"key":"6727_CR32","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1158\/2159-8290.CD-13-0846","volume":"4","author":"L Friboulet","year":"2014","unstructured":"Friboulet L, Li N, Katayama R et al (2014) The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 4:662\u2013673. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0846","journal-title":"Cancer Discov"},{"key":"6727_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00579","volume":"9","author":"MW Alam","year":"2019","unstructured":"Alam MW, Boren\u00e4s M, Lind DE et al (2019) Alectinib, an anaplastic lymphoma kinase inhibitor, abolishes ALK activity and growth in ALK-positive neuroblastoma cells. Front Oncol 9:579. https:\/\/doi.org\/10.3389\/fonc.2019.00579","journal-title":"Front Oncol"},{"key":"6727_CR34","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/s43018-022-00390-1","volume":"3","author":"L He","year":"2022","unstructured":"He L, Dar AC (2022) Targeting drug-resistant mutations in ALK. Nat Cancer 3:659\u2013661. https:\/\/doi.org\/10.1038\/s43018-022-00390-1","journal-title":"Nat Cancer"},{"key":"6727_CR35","doi-asserted-by":"publisher","first-page":"5527","DOI":"10.1158\/1078-0432.CCR-16-0569","volume":"22","author":"S Zhang","year":"2016","unstructured":"Zhang S, Anjum R, Squillace R et al (2016) The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical models. Clin Cancer Res 22:5527\u20135538. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0569","journal-title":"Clin Cancer Res"},{"key":"6727_CR36","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1242\/DMM.024448","volume":"9","author":"J Guan","year":"2016","unstructured":"Guan J, Tucker ER, Wan H et al (2016) The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN. Dis Model Mech 9:941\u2013952. https:\/\/doi.org\/10.1242\/DMM.024448","journal-title":"Dis Model Mech"},{"key":"6727_CR37","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1158\/2159-8290.CD-15-1056","volume":"6","author":"NR Infarinato","year":"2016","unstructured":"Infarinato NR, Park JH, Krytska K et al (2016) The ALK\/ROS1 inhibitor PF-06463922 overcomes primary resistance to crizotinib in ALK-driven neuroblastoma. Cancer Discov 6:96\u2013107. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-1056","journal-title":"Cancer Discov"},{"key":"6727_CR38","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/J.CCELL.2015.05.010","volume":"28","author":"HY Zou","year":"2015","unstructured":"Zou HY, Friboulet L, Kodack DP et al (2015) PF-06463922, an ALK\/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell 28:70\u201381. https:\/\/doi.org\/10.1016\/J.CCELL.2015.05.010","journal-title":"Cancer Cell"},{"key":"6727_CR39","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3390\/cancers10030062","volume":"10","author":"GG Sharma","year":"2018","unstructured":"Sharma GG, Mota I, Mologni L et al (2018) Tumor resistance against ALK targeted therapy-Where it comes from and where it goes. Cancers (Basel) 10:62","journal-title":"Cancers (Basel)"},{"key":"6727_CR40","doi-asserted-by":"publisher","first-page":"6342","DOI":"10.1021\/jm2007613","volume":"54","author":"JJ Cui","year":"2011","unstructured":"Cui JJ, Tran-Dub\u00e9 M, Shen H et al (2011) Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 54:6342\u20136363. https:\/\/doi.org\/10.1021\/jm2007613","journal-title":"J Med Chem"},{"key":"6727_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.111368","volume":"27","author":"M Shi","year":"2024","unstructured":"Shi M, Wang F, Lu Z et al (2024) Elucidating the linagliptin and fibroblast activation protein binding mechanism through molecular dynamics and binding free energy analysis. iScience 27:111368. https:\/\/doi.org\/10.1016\/j.isci.2024.111368","journal-title":"iScience"},{"key":"6727_CR42","doi-asserted-by":"crossref","unstructured":"Passaro S, Corso G, Wohlwend J et al (2025) Boltz-2: Towards Accurate and Efficient Binding Affinity Prediction","DOI":"10.1101\/2025.06.14.659707"},{"key":"6727_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065821","author":"SY Cheon","year":"2023","unstructured":"Cheon SY, Kwon S (2023) Molecular anatomy of the EML4-ALK fusion protein for the development of novel anticancer drugs. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24065821","journal-title":"Int J Mol Sci"},{"key":"6727_CR44","doi-asserted-by":"publisher","first-page":"37447","DOI":"10.1074\/jbc.M112.391425","volume":"287","author":"LF Epstein","year":"2012","unstructured":"Epstein LF, Chen H, Emkey R, Whittington DA (2012) The R1275Q neuroblastoma mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of anaplastic lymphoma kinase. J Biol Chem 287:37447\u201337457. https:\/\/doi.org\/10.1074\/jbc.M112.391425","journal-title":"J Biol Chem"},{"key":"6727_CR45","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1039\/c4mb00141a","volume":"10","author":"TG Karabencheva","year":"2014","unstructured":"Karabencheva TG, Lee CC, Black GW et al (2014) How does conformational flexibility influence key structural features involved in activation of anaplastic lymphoma kinase? Mol Biosyst 10:1490\u20131495. https:\/\/doi.org\/10.1039\/c4mb00141a","journal-title":"Mol Biosyst"},{"key":"6727_CR46","doi-asserted-by":"publisher","first-page":"6813","DOI":"10.1021\/bi1005514","volume":"49","author":"RT Bossi","year":"2010","unstructured":"Bossi RT, Saccardo MB, Ardini E et al (2010) Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. Biochemistry 49:6813\u20136825. https:\/\/doi.org\/10.1021\/bi1005514","journal-title":"Biochemistry"},{"key":"6727_CR47","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/jha2.646","volume":"4","author":"K Noguchi","year":"2023","unstructured":"Noguchi K, Ikawa Y, Takenaka M et al (2023) Acquired L1196M ALK mutation in anaplastic lymphoma kinase\u2010positive anaplastic large cell lymphoma during alectinib administration. EJHaem 4:305\u2013308. https:\/\/doi.org\/10.1002\/jha2.646","journal-title":"EJHaem"},{"key":"6727_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2022.110264","author":"J Shen","year":"2022","unstructured":"Shen J, Meng Y, Wang K et al (2022) EML4-ALK G1202R mutation induces EMT and confers resistance to ceritinib in NSCLC cells via activation of STAT3\/Slug signaling. Cell Signal. https:\/\/doi.org\/10.1016\/j.cellsig.2022.110264","journal-title":"Cell Signal"},{"key":"6727_CR49","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/cam4.413","volume":"4","author":"D Fontana","year":"2015","unstructured":"Fontana D, Ceccon M, Gambacorti-Passerini C, Mologni L (2015) Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK. Cancer Med 4:953\u2013965. https:\/\/doi.org\/10.1002\/cam4.413","journal-title":"Cancer Med"},{"key":"6727_CR50","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2024.25","author":"D Poei","year":"2024","unstructured":"Poei D, Ali S, Ye S, Hsu R (2024) Alk inhibitors in cancer: mechanisms of resistance and therapeutic management strategies. Cancer Drug Resist. https:\/\/doi.org\/10.20517\/cdr.2024.25","journal-title":"Cancer Drug Resist"}],"container-title":["Journal of Molecular Modeling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00894-026-06727-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00894-026-06727-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00894-026-06727-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T06:13:53Z","timestamp":1778307233000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00894-026-06727-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["6727"],"URL":"https:\/\/doi.org\/10.1007\/s00894-026-06727-2","relation":{},"ISSN":["1610-2940","0948-5023"],"issn-type":[{"value":"1610-2940","type":"print"},{"value":"0948-5023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"assertion":[{"value":"1 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"144"}}